NCT07501117

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Inge Marie Svane · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.

Conditions

• Uveal Melanoma

Interventions

Type	Name	Description
DRUG	Nivolumab & Ipilimumab	Nivolumab 3 mg/kg Ipilimumab 1 mg/kg

Timeline

• Start date: 2026-05-01
• Primary completion: 2029-04-01
• Completion: 2029-04-01
• First posted: 2026-03-30
• Last updated: 2026-03-30

Locations

1 site across 1 country: Denmark